# GSK corporate restructuring and financial performance

> Live situation record from CLSTR: https://clstr.news/situations/gsk-corporate-restructuring-and-financial-performance
> Updated: 2026-08-16T10:01:26.000Z. Sources: 2. Developments: 2.

GlaxoSmithKline (GSK) is undergoing significant structural and financial shifts. The company announced a £1.9 billion cost-cutting programme that includes a £400 million investment in UK life sciences. This plan involves relocating over 1,000 scientists to a new research centre on the Cambridge Biomedical Campus and closing its Stevenage R&D hub by 2029.

Despite these strategic moves and recent profit boosts in Specialty Medicines and Vaccines—which helped 2025 profits reach £7.93bn—the company faces long-term growth challenges. Historical difficulties include pipeline disappointments, patent expiries, high R&D costs, and multi-billion pound Zantac settlement provisions. While recent share performance has shown positive growth, the company continues to navigate the complexities of its research and development investments and market value.

## Timeline

### 2026-08-16: GSK faces long-term growth challenges despite recent profit boosts

GSK has experienced modest long-term growth due to R&D costs, patent expiries, and legal settlements, despite recent boosts in Specialty Medicines and Vaccines.

2 sources. https://clstr.news/cluster/gsk-faces-long-term-growth-challenges-despite-recent-profit-boosts

### 2026-07-28: GSK launches £1.9bn cost‑cut plan, shifts R&D to Cambridge, closes Stevenage hub

GSK’s £1.9bn cost‑cutting plan adds a £400m UK life‑science investment, builds a new Cambridge R&D campus and will close its Stevenage hub by 2029, prompting job cuts.

9 sources. https://clstr.news/cluster/gsk-launches-19bn-costcut-plan-shifts-rd-to-cambridge-closes-stevenage-hub

---
Cite as: GSK corporate restructuring and financial performance. CLSTR, https://clstr.news/situations/gsk-corporate-restructuring-and-financial-performance